Tiedote -
Inflammatory Bowel Disease Treatment Market Size, CAGR, Trends, Consumption, Production, Revenue and Forecast 2020 - 2027
The global inflammatory bowel disease treatment market size surpassed at US$ 15.8 Bn in 2020 and to reach USD$ 27.2 billion by 2027 with a 6.2% CAGR during the forecast period 2020 to 2027.
Inflammatory bowel disease is a group of medical conditions that causes chronic inflammation in the digestive tract. Inflammatory bowel disease is an umbrella term that comprises two principal disorders: ulcerative colitis and Crohn’s disease. Ulcerative colitis is a long-term medical indication that causes inflammation and sores in the inner lining of the colon and rectum. Crohn’s disease is part of inflammatory bowel disease that causes inflammation to any part of the gastrointestinal tract, right from mouth to small intestine and anus. The exact cause of inflammatory bowel disease is not known; however, autoimmune disorders, genetic factors, and lifestyle changes are thought to cause the symptoms of inflammatory bowel disease in an individual. The common symptoms of inflammatory bowel disease include diarrhea, abdominal pain & cramps, constipation, rectal bleeding, weight loss, and fever.
Inflammatory bowel disease (IBD) affects men and women equally, and is more commonly observed in developed countries in the West than developing and underdeveloped countries. There is no permanent cure for this disease, and it requires lifetime treatment and management. However, the most preferred treatment option includes administration of medications such as aminosalicyclates, corticosteroids, biologic drugs, and integrin antagonists. In severe conditions, surgical treatments are also recommended.
Get Sample Pages of Report@ https://www.visionresearchreports.com/report/sample/35705
Growth of the global IBD (ulcerative colitis and Crohn’s disease) treatment market can be attributed to rise in the prevalence of inflammatory bowel diseases across the world, development of novel drugs, novel pipeline drugs, and increase in access to the treatment of IBD. The availability and launch of biosimilar drugs for the treatment of IBD and rise in the adoption of biologic drugs are the other factors fueling the growth of the global IBD (ulcerative colitis and Crohn’s disease) treatment market. Rise in investments in building a robust pipeline for IBD and increase in lifestyle-related risk factors are likely to boost the growth of the global IBD treatment market.
North America dominated the global IBD (ulcerative colitis and Crohn’s disease) treatment market in 2019, and the trend is anticipated to continue during the forecast period. This can be ascribed to the presence of key players, increase in incidence of IBD, favorable reimbursement policies, and availability of novel drugs for IBD. However, the adverse side effects associated with IBD drugs and high cost of treatment are likely to restrain the global IBD treatment market during the forecast period.
New Product Development & Approvals to Drive Global Market
Inflammatory bowel diseases are characterized by chronic inflammation in the gastrointestinal tract, and primarily include Crohn’s disease and ulcerative colitis disease. The exact cause of inflammatory bowel disease is not known, and the high prevalence of these diseases has been witnessed in developed countries. Several medications such as corticosteroids, aminosalicylates, integrin antagonists, biologic drugs such as Tumor Necrosis Factor (TNF) inhibitors, and up to a certain extent, antibiotic drugs, are prescribed to provide relief from the symptoms of these diseases.
The high prevalence and increase in incidence of Crohn’s disease and ulcerative colitis disease in developed countries has led to the development of novel therapeutics drugs. Biopharmaceutical companies have made significant investments in R&D, and numerous pipeline products are in various stages of clinical approvals, and likely to be commercialized during the forecast period. AstraZeneca and Allergan are together developing the MEDI2070 interleukin-23 monoclonal antibody against ulcerative colitis and Crohn’s disease. MEDI2070 is currently in phase IIb of clinical trial for moderate to severe Crohn’s disease, and in phase II for ulcerative colitis. Pfizer's PF-00547659 and Celgene’s Ozanimod are in phase II and phase III clinical trials, for Crohn’s Disease and ulcerative colitis, respectively. Additionally, the recent launch and approval of new drugs in North America, Europe, and Japan are projected to fuel the demand for IBD treatment drugs in the near future.
Increase in Lifestyle-related Risk Factors to Drive Market
The exact cause of inflammatory bowel disease is not known; however, researchers consider the combination of several factors such as autoimmune diseases, genetic factors, unhealthy lifestyles, smoking, and environment that lead to the development of symptoms of inflammatory bowel disease. High dosage and regular administration of antibiotics to treat various chronic as well as infectious diseases pose the risk of developing inflammatory bowel disease. Moreover, dosage of non-steroidal anti-inflammatory drugs such as aspirin and ibuprofen increases the risk of developing IBD. No specific food is found to be responsible for IBD; however, for some people, high consumption of specific types of foods, such as junk food, has resulted in the development of IBD. Other factors such as autoimmune diseases, sedentary lifestyle, lack of exercise, and high stress levels could cause IBD symptoms.
Purchase this Premium Research Report@ https://www.visionresearchreports.com/report/cart/35705
Integrin Antagonists Drug Class to Lead Global Market
In terms of drug class, the global market has been classified into TNF inhibitors, aminosalicyclates, integrin antagonists, and corticosteroids. TNF inhibitors comprise biologics and biosimilar drugs that are used as second-line treatment when patients fail to respond to other pharmaceutical drugs. The TNF inhibitors segment is projected to account for a major share of the global IBD (ulcerative colitis and Crohn’s disease) treatment market. TNF inhibitors are monoclonal antibodies developed from human and animal tissues, and are used to stop inflammation in the bowels. The segment accounted for the largest market share in 2019 and is anticipated to gain market share by the end of 2027. The most commonly and frequently used TNF inhibitors include adalimumab, vedolizumab, and infliximab. The integrin antagonists segment is expected to expand at the highest CAGR of ~10% during the forecast period.
Ulcerative Colitis Disease Indication Most Prevalent
In terms of disease indication, the global IBD (ulcerative colitis and Crohn’s disease) treatment market has been segmented into ulcerative colitis and Crohn’s disease. The ulcerative colitis segment dominated the global market in 2019, and the trend is likely to continue during the forecast period. The high prevalence and incidence of ulcerative colitis in Europe and North America, increase in awareness about the disease, and surge in the number of hospitalizations for ulcerative colitis are projected to drive the ulcerative colitis segment in the IBD (ulcerative colitis and Crohn’s disease) treatment market during the forecast period.
Retail Pharmacies to Lead Global Market
In terms of distribution channel, the global IBD treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held the largest market share in 2019, and the trend is anticipated to continue during the forecast period. An increase in retail pharmacy chains across the globe is resulting in the easy availability of IBD drugs. This, in turn, is expected to boost the growth of the segment. The U.S. has around 67,000 pharmacies. Walmart Stores, Inc. and Walgreens are the largest retail pharmacy stores in the country. Furthermore, the availability of biologics and novel drugs at retail pharmacy chains and tie-ups of hospitals with these chains are attributed to the segment’s dominance of the global IBD (ulcerative colitis and Crohn’s disease) treatment market.
Regional Insights
In terms of region, the global IBD (ulcerative colitis and Crohn’s disease) treatment market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global IBD (ulcerative colitis and Crohn’s disease) treatment market in 2019, followed by Europe.
North America accounted for a major share of the global market in 2019. This can be attributed to new product development, especially biologic drugs and approvals, well-established healthcare facilities, highest prevalence and incidence rates of IBD, and presence of key players in the region. Moreover, new pipeline products, increased clinical R&D budgets by both, government as well as private players, and rise in lifestyle-related risk factors are likely to fuel the demand for IBD treatments during the forecast period. The market in Asia Pacific is projected to expand at the highest CAGR during the forecast period, owing to the large number of patients suffering from IBD disease in India, China, Australia, and New Zealand, rise in per capita medical expenditure, and increase in access to healthcare. The IBD (ulcerative colitis and Crohn’s disease) treatment markets in Latin America and the Middle East & Africa are likely to grow at a moderate pace during the forecast period.
Innovative Product Launches and Mergers & Acquisitions by Key Players to Drive Market
The global IBD (ulcerative colitis and Crohn’s disease) treatment market is consolidated in terms of number of players. A small number of players account for a majority share of the global market. Key players operating in the global IBD treatment market include Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB, Inc., and Biogen, Inc. These players have adopted various strategies such as product portfolio expansion, investment in research & development, development of novel IBD (ulcerative colitis and Crohn’s disease) treatment, and mergers & acquisitions to establish a strong distribution network. For instance, in February 2019, Janssen Biotech, Inc. and Theravance Biopharma, Inc. entered into a worldwide collaboration to develop TD-1473 for the treatment of inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease. In April 2020, Salix Pharmaceuticals entered into an exclusive license agreement with Mitsubishi Tanabe Pharma to commercialize and develop late stage investigational S1P modulators for the treatment of inflammatory bowel disease.
Market: Segmentation
By Drug Class
- TNF Inhibitors
- Aminosalicylates
- Integrin Antagonists
- Corticosteroids
- Others
By Disease Indication
- Ulcerative Colitis
- Crohn’s Disease
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- NORDIC
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- ASEAN
- ANZ
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Rest of Latin America
Scope of the Report
VRR’S report on the global IBD (ulcerative colitis and Crohn’s disease) treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market for the forecast period of 2020 to 2027. The report provides the overall market revenue of the global IBD (ulcerative colitis and Crohn’s disease) treatment market for the period of 2016–2027, considering 2020 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global IBD treatment market for the forecast period.
The report has been prepared after extensive research. Primary research involves bulk of the research efforts, wherein, analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global IBD (ulcerative colitis and Crohn’s disease) treatment market.
Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of the top-down and bottom-up approaches to study various phenomena in the global IBD (ulcerative colitis and Crohn’s disease) treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the global IBD (ulcerative colitis and Crohn’s disease) treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global IBD treatment market. The next section of the global IBD (ulcerative colitis and Crohn’s disease) treatment report highlights the USPs, which include disease prevalence: IBD (ulcerative colitis and Crohn’s disease) globally, IBD (ulcerative colitis and Crohn’s disease) treatment pipeline analysis, and major deals and strategic alliances analysis in the global IBD (ulcerative colitis and Crohn’s disease) treatment market.
The report delves into the competitive landscape of the global IBD (ulcerative colitis and Crohn’s disease) treatment market. Key players operating in the global IBD treatment market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overviews, financial standings, recent developments, and SWOT are some of the attributes of the players profiled in the global IBD (ulcerative colitis and Crohn’s disease) treatment market report.
Key Questions Answered
- What is the sales/revenue expected to be generated by IBD (ulcerative colitis and Crohn’s disease) treatment products across all the regions during the forecast period?
- What are the key trends in the IBD (ulcerative colitis and Crohn’s disease) treatment market?
- What are the major drivers, restraints, and opportunities in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment will have the highest revenue, globally, in 2027, and which product segment will expand at the fastest CAGR during the forecast period?
Research Objectives and Research Approach
The comprehensive report on the global IBD (ulcerative colitis and Crohn’s disease) treatment market begins with an overview of the said market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of this study and healthcare compliances laid down by accredited agencies in the purview of research in the global IBD (ulcerative colitis and Crohn’s disease) treatment market. It is followed by a market introduction, market dynamics, and an overview of the global IBD treatment market, which includes VRR’s analysis of the market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights have been provided to understand the Y-o-Y trends of the IBD (ulcerative colitis and Crohn’s disease) treatment market. The next section of the global IBD (ulcerative colitis and Crohn’s disease) treatment report highlights the USPs, including disease prevalence, globally, treatment pipeline analysis, and major deals & strategic alliance analysis in the global IBD (ulcerative colitis and Crohn’s disease) treatment market.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of the key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
Revenue generated by key IBD (ulcerative colitis and Crohn’s disease) treatment players has been mapped to ascertain the size of the global IBD (ulcerative colitis and Crohn’s disease) treatment market in terms of value. The forecasts presented here assess the total revenue generated in the IBD (ulcerative colitis and Crohn’s disease) treatment market. In order to provide an accurate forecast, we initiated by sizing up the current IBD (ulcerative colitis and Crohn’s disease) treatment market with the help of the parent market.
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Inflammatory Bowel Disease Treatment Market, By Drug Class
7.1. Inflammatory Bowel Disease Treatment Market, by Drug Class Type, 2020-2027
7.1.1. TNF Inhibitors
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Aminosalicylates
7.1.2.1. Market Revenue and Forecast (2016-2027)
7.1.3. Integrin Antagonists
7.1.3.1. Market Revenue and Forecast (2016-2027)
7.1.4. Corticosteroids
7.1.4.1. Market Revenue and Forecast (2016-2027)
7.1.5. Others
7.1.5.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global Inflammatory Bowel Disease Treatment Market, By Disease Indication
8.1. Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2020-2027
8.1.1. Ulcerative Colitis
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Crohn’s Disease
8.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Inflammatory Bowel Disease Treatment Market, By Distribution Channel
9.1. Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2020-2027
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 10. Global Inflammatory Bowel Disease Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.1.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.1.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.1.4.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.1.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.1.5.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.1.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.2.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.2.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.2.4.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.2.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.2.5.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.2.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.2.6.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.2.6.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.2.7.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.2.7.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.3.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.3.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.3.4.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.3.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.3.5.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.3.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.3.6.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.3.6.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.3.7.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.3.7.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.4.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.4.4.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.4.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.4.5.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.4.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.4.6.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.4.6.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.4.7.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.4.7.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.5.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.5.4.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.5.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.5.5.2. Market Revenue and Forecast, by Disease Indication (2016-2027)
10.5.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
Chapter 11. Company Profiles
11.1. Valeant Pharmaceuticals International, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Allergan plc
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Pfizer, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Janssen Biotech, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Takeda Pharmaceutical Company Limited.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. AbbVie, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Novartis AG
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. UCB, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Biogen, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Aiheet
- Terveydenhoito
Kategoriat
- inflammatory bowel disease treatment market
- inflammatory bowel disease treatment market size
- inflammatory bowel disease treatment market share